Dyslipidemia in diabetic patients is often combined with elevated TG and reduced HDL-C in addition to elevated LDL-C. There is a small, dense LDL in LDL-C, which is a major atherogenic particle. Statin lipid-lowering drugs mainly work on LDL-C and total cholesterol, while fenofibrate mainly lowers TG, raises HDL-C, and mildly lowers LDL-C. When a patient is diagnosed with diabetes, we need to pay attention to his lipid profile, and when the patient has high LDL-C, we need to use statins, and when the patient has high TG and low HDL-C, we need to use fibrates or a combination of both. Studies have shown that statins can reduce macroangiopathy in diabetics, while betablockers have a more pronounced microvascular protective effect and can reduce amputations, retinopathy and can have a renal protective effect.